Results 141–160 of 305 for speaker:Lord Freyberg

Written Answers — Department of Health: Cancer (3 Mar 2016)

Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 4 February (HL5344) and on 11 February (HL5970), how many of the 8,000 expected clinical reports are in the cancer part of that project, as compared to the rare disease; and in the cancer part of that project, how many are planned for delivery by the end of (1) March, (2) June, and (3) September.

Access to Medical Treatments (Innovation) Bill: Second Reading (26 Feb 2016)

Lord Freyberg: My Lords, I, too, am delighted to support the Bill. I speak today, as many noble Lords do, as one touched by the tragedy of cancer. As some noble Lords may know, my sister died two years of mesothelioma. Recent data from the Office for National Statistics show that 43% of cancers are less common cancers such as mesothelioma. While each is small, collectively they account for well over half of...

Written Answers — Cabinet Office: Cancer (15 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Bridges of Headley on 26 January (HL5030), what historic data they hold on cancer registrations and deaths in England over the past 15 years owing to: (1) C50, malignant neoplasm of breast, (2) C61, malignant neoplasm of prostate, (3) C33-C34, malignant neoplasm of trachea, bronchus and lung, (4) C18-C20, malignant...

Written Answers — Cabinet Office: Cancer (15 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what has been the one-year survival rate for each of the last 15 years with regard to: (1) C50, malignant neoplasm of breast, (2) C61, malignant neoplasm of prostate, (3) C33-C34, malignant neoplasm of trachea, bronchus and lung, (4) C18-C20, malignant neoplasm of colon and rectum, (5) C43, malignant melanoma of skin, (6) C82-C85, non-Hodgkin’s lymphoma,...

Written Answers — Department of Health: Cancer (11 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5341), what consideration the NHS has given to offering to share outcome data with test providers, where suitable consents can be captured, on the forthcoming re-procurement of the NHS regional genetics labs, such as from the National Cancer Intelligence Network; and what assessment...

Written Answers — Department of Health: Cancer (11 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5343), what assessment Genomic England or the NHS has made of the Broad Institute’s TARGET database of clinically actionable mutations, and whether they have anything further to add to that answer in the light of the fact that a mutation is not clinically actionable unless a drug is...

Written Answers — Department of Health: Cancer (11 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5344), when Genomic England expects to have reported back to patients from the pilot phase on (1) 100 patients, (2) 250 patients, (3) 500 patients, (4) 1000 patients, and (5) all patients.

Written Answers — Department of Health: Cancer (11 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5345), how many of the 20 patients with reports issued so far by the Genomic England cancer project had (1) a clinically actionable mutation for which the NHS will reimburse the costs of the treatment drug, and (2) a clinically actionable mutation for any trial currently open in the UK;...

Written Answers — Department of Health: Cancer (8 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what advice they received from the Wellcome Trust Sanger Institute during the set-up phase of Genomics England regarding the appropriateness in cases of cancer of using comparisons of tumour to normal whole genome sequencing at moderate sequence coverage, as opposed to focused actionable gene panel testing at deep sequence coverage; and what current...

Written Answers — Department of Health: Diseases (8 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what estimate they have made of how many (1) definitive, and (2) actionable, diagnoses in rare diseases can be made on the existing rare disease sequencing budget of Genomic England in 2016; whether Genomic England used (a) whole genome sequencing, (b) whole exome sequencing, or (c) medical exome sequencing; and if those estimates are not available, why not.

Written Answers — Department for Education: Gcse (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what percentage of candidates in (1) 2013, (2) 2014, and (3) 2015, achieved grade A*-C or a pass for (a) seven or more GCSEs, (b) five or six GCSEs, (c) four or five GCSEs, (d) three or four GCSEs, (e) two or three GCSEs, (f) one GCSE, and (g) no GCSEs, broken down into socio-economic groups.

Written Answers — Department of Health: Cancer (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what are the costs, rather than the tariff, of a cancer molecular profile using (1) a whole tumour-normal pair using Illumina technology at 70× tumour coverage, and (2) a deep sequenced next-generation sequencing panel test, as deployed in most major NHS teaching hospitals; and if those figures are not available, why not.

Written Answers — Department of Health: Cancer (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what estimate they have made of how many cancer patients could receive a molecular test on Genomics England’s cancer sequencing budget for 2016 if Genomics England (1) continued to use whole genome sequencing on tumour and normal tissue pairs, and (2) switched to deep sequenced panel tests.

Written Answers — Department of Health: Cancer (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government whether the cancer panel test used at the main NHS tertiary hospitals will provide the vast majority of clinically actionable information in a tumour genome, in the light of the NHS reimbursement environment for targeted therapies.

Written Answers — Department of Health: Cancer (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government how many successful tumour-normal genomes Genomics England has sequenced, interpreted and returned to patients to date; how long on average it has taken to return those results to patients; and how many cancer patients have died without receiving their results after supplying tumour samples to the 100,000 Genomes Project.

Written Answers — Department of Health: Diseases (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government how many (1) definitive, and (2) actionable, diagnoses are made for every 1,000 genomes sequenced as part of the rare disease arm of 100,000 Genomes Project; and how many diagnoses they estimate would have been made if the Project were run using (1) whole, and (2) medical, exome technology; and if those estimates are not available, why not.

Written Answers — Department of Health: Diseases (4 Feb 2016)

Lord Freyberg: To ask Her Majesty’s Government what are the costs per test in rare disease treatment using (1) whole genome, (2) whole exome, and (3) medical exome, sequencing; and if those figures are not available, why not.

Written Answers — Cabinet Office: Cancer (26 Jan 2016)

Lord Freyberg: To ask Her Majesty’s Government what are the latest figures for the total number and percentage of incidence of cancers and total deaths excluding non-melanoma skin cancer, for (1) the top five occurring cancers, including breast, prostate, colorectal, lung, and melanoma, (2) less common cancers with an incidence ranked six to 15 by the International Classification of Diseases code, and (3)...

Written Answers — Department of Health: Cancer (26 Jan 2016)

Lord Freyberg: To ask Her Majesty’s Government what information (1) the National Cancer Intelligence Network, (2) Public Health England, (3) the National Institute for Health Research, and (4) the NHS more broadly, hold on mesothelioma and other less common cancers covering (a) hospital surgical volumes; (b) hospital systemic anti-cancer treatment volumes; (c) hospital radiotherapy volumes; (d) clinical...

Health: Cancer — Question for Short Debate (20 Jan 2016)

Lord Freyberg: My Lords, I begin my speech with a startling fact: rare cancers accounted for 43% of cases in 2010, but 59% of cancer deaths. Let me repeat that: these less common cancers affect roughly four in 10 of new patients, but make up six in 10 of deaths. If we want to improve survival overall we have to improve our performance in these cancers, and our performance in caring for them is poor relative...


<< < 1 2 3 4 5 6 7 8 9 10 > >>

Create an alert

Did you find what you were looking for?

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range

to

You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989

Person

Enter a name here to restrict results to contributions only by that person.

Section

Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.

Column

If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.